4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000065
President & Immunovant CEO sold 200,000 shares at $30.27 ($6,054,000)
- President & Immunovant CEO gave up 34,483 shares (to pay taxes)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Venker Eric · President & Immunovant CEO
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-05-20 | Shares withheld for taxes : show line 1 in the form 10b5-1 | −34,483 | $32.41 | $1,117,594 | 1,613,063 | D |
| 2026-05-22 | Exercise or conversion : show line 2 in the form 10b5-1 | +200,000 | $3.85 | $770,000 | 1,813,063 | D |
| 2026-05-22 | Sale : show line 3 in the form 10b5-1 | −200,000 | $30.27 | $6,054,000 | 1,613,063 | D |
| Open-market sales · 200,000 sh · avg $30.27 · $6,054,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-05-22 | Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) | −200,000 | 4,444,834 | D |
Loading xslF345X06/wk-form4_1779488744.xml…